Technical Analysis for RAC - Race Oncology Ltd  

Grade Last Price % Change Price Change
D 1.395 -3.79% -0.055
RAC closed down 3.79 percent on Tuesday, November 19, 2024, on 1.53 times normal volume.
Earnings due: Nov 26
*** please verify all earnings dates ***
4 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Down Down

Date Alert Name Type % Chg
Lower Bollinger Band Walk Weakness 0.00%
Lower Bollinger Band Touch Weakness 0.00%
Hammer Candlestick Bullish -3.79%
Lizard Bullish Bullish Day Trade Setup -3.79%
Doji - Bullish? Reversal -3.79%
Lower Bollinger Band Touch Weakness -3.79%
Oversold Stochastic Weakness -3.79%
Oversold Stochastic Weakness -3.79%
200 DMA Resistance Bearish -1.76%
MACD Bearish Signal Line Cross Bearish -1.76%

   Recent Intraday Alerts

Alert Time
Lower Bollinger Band Support about 8 hours ago
2x Volume Pace about 11 hours ago
Fell Below Previous Day's Low about 11 hours ago
Down 1 ATR about 11 hours ago
Down 5% about 11 hours ago

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Race Oncology Ltd   Description

Race Oncology Limited, formerly Coronado Resources Limited, is an Australia-based specialty pharmaceutical company whose business model is to pursue and bring to market later stage assets, principally in the cancer field. The Company's Bisantrene drug is a chemotherapy drug, which is related to the anthracyclines, a class of drugs used as the first line of treatment for acute myeloid leukemia (AML) and other cancers. Its Bisantrene drug reduces cardiac toxicity compared to anthracyclines and to be effective against some cancers that have relapsed after the patients have already received high levels of anthracyclines, which makes Bisantrene as a second- or third-line treatment for patients reaching their cardio-toxic limit of anthracyclines or whose cancer has become resistant to anthracycline treatment. It has received orphan drug designation for Bisantrene in the United States. Its clinical opportunity for Bisantrene is used as a salvage treatment for elderly patients with AML.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Pharmaceutical Cancer Drugs Clinical Medicine Cancers Therapy Oncology Chemotherapy Isan Leukemia

Is RAC a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 2.09
52 Week Low 0.64
Average Volume 101,484
200-Day Moving Average 1.490
50-Day Moving Average 1.589
20-Day Moving Average 1.487
10-Day Moving Average 1.491
Average True Range 0.077
RSI (14) 39.02
ADX 20.45
+DI 12.362
-DI 26.622
Chandelier Exit (Long, 3 ATRs) 1.415
Chandelier Exit (Short, 3 ATRs) 1.560
Upper Bollinger Bands 1.606
Lower Bollinger Band 1.367
Percent B (%b) 0.12
BandWidth 16.078
MACD Line -0.037
MACD Signal Line -0.030
MACD Histogram -0.0065
Fundamentals Value
Market Cap 178.78 Million
Num Shares 128 Million
EPS -0.05
Price-to-Earnings (P/E) Ratio -30.33
Price-to-Sales 0.00
Price-to-Book 48.43
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 1.575
Resistance 3 (R3) 1.573 1.512 1.545
Resistance 2 (R2) 1.512 1.466 1.513 1.535
Resistance 1 (R1) 1.453 1.438 1.423 1.455 1.525
Pivot Point 1.392 1.392 1.376 1.393 1.392
Support 1 (S1) 1.333 1.346 1.303 1.335 1.265
Support 2 (S2) 1.272 1.318 1.273 1.255
Support 3 (S3) 1.213 1.272 1.245
Support 4 (S4) 1.215